Migdal Insurance & Financial Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-145	Closed	-$64.7K	–	428
2026 Q1	$64.7K	Buy	+145	New	+$67.6K	﹤0.01%	270
2025 Q4	–	Sell	-75,000	Closed	-$29.4M	–	390
2025 Q3	$29.4M	Buy	+75,000	New	+$31.3M	0.32%	51
2021 Q4	–	Sell	-1,401	Closed	-$254K	–	736
2021 Q3	$254K	Buy	1,401 +602	+75%	+$118K	﹤0.01%	275
2021 Q2	$160K	Sell	799 -2,547	-76%	-$533K	﹤0.01%	343
2021 Q1	$677K	Buy	3,346 +2,204	+193%	+$484K	0.01%	290
2020 Q4	$270K	Buy	+1,142	New	+$262K	﹤0.01%	281
2018 Q4	–	Sell	-1,823	Closed	-$351K	–	813
2018 Q3	$351K	Buy	1,823 +1,081	+146%	+$192K	0.01%	456
2018 Q2	$126K	Buy	742 +719	+3,126%	+$111K	﹤0.01%	482
2018 Q1	$4K	Buy	+23	New	+$3.76K	﹤0.01%	582

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Migdal Insurance & Financial Holdings's VRTX Position: Q2 2026 in Review

Migdal Insurance & Financial Holdings sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 145 shares — an estimated $64.7K sold.

Migdal Insurance & Financial Holdings first reported a position in VRTX in Q1 2018 and held it in 9 quarters. The position peaked at $29.4M in Q3 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Migdal Insurance & Financial Holdings reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Migdal Insurance & Financial Holdings sold 145 Vertex Pharmaceuticals shares in Q2 2026, an estimated $64.7K.
Migdal Insurance & Financial Holdings first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Migdal Insurance & Financial Holdings's Vertex Pharmaceuticals position peaked at $29.4M in Q3 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2026, filed 10 Aug 2026.